What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel
Thienopyridines are a class of drug targeting the platelet adenosine diphosphate 2 receptor. They have been shown to significantly reduce platelet activity exerting an important role in those clinical settings in which such an effect is beneficial. Ticlopidine was first to be introduced several year...
Gespeichert in:
| Veröffentlicht in: | QJM : An International Journal of Medicine 2010-06, Vol.103 (6), p.367-377 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 377 |
|---|---|
| container_issue | 6 |
| container_start_page | 367 |
| container_title | QJM : An International Journal of Medicine |
| container_volume | 103 |
| creator | Testa, L. Bhindi, R. Van Gaal, W.J. Latini, R.A. Pizzocri, S. Lanotte, S. Biondi Zoccai, G.G.L. Valgimigli, M. Laudisa, M.L. Brambilla, N. Banning, A.P. Bedogni, F. |
| description | Thienopyridines are a class of drug targeting the platelet adenosine diphosphate 2 receptor. They have been shown to significantly reduce platelet activity exerting an important role in those clinical settings in which such an effect is beneficial. Ticlopidine was first to be introduced several years ago but it was quickly replaced by clopidogrel as it had a better risk/benefit profile. Recently, prasugrel has been developed and tested in several ex vivo studies and clinical trials showing able to provide a more powerful antiplatelet effect at the expense of a higher risk of bleeding complications. Great debate rose around its recent approval in the US as well as in Europe. This review aims at exploring the development and available clinical data of this third-generation thienopyridine while discussing its practical implementation in routine practice. |
| doi_str_mv | 10.1093/qjmed/hcq017 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733561630</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733561630</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-1789327dfde104aed404c3aa554056d7a0b28216258c2a919bee5334cd69179c3</originalsourceid><addsrcrecordid>eNpFkU9v1DAQxSMEoqVw44x8Qb2Q1v8SxydUVbSlWqlCAoq4WBNn0nWbjbO2F9gvwWeut7sLJz_N_PxGeq8o3jJ6wqgWp8v7BXanc7ukTD0rDpmsacmFFs_3WvHqoHgV4z2lVCrZvCwOOOWMNbI5LP7eziERF0maIwkuPhDfEzcmHKPr1268I9MACQfM0Dh3rUvOj6TFtR87Ygc_uc7fBRw-kjMS1zHhApKzJOAvh78JZAiIDfmXhYHANAVwMat85OmgH3Cj8ziuNjavixc9DBHf7N6j4tvFp6_nV-Xs5vLz-dmstELXqWSq0YKrru-QUQnYSSqtAKgqSau6U0Bb3nBW86qxHDTTLWIlhLRdrZnSVhwVx1vfKfjlCmMyCxctDgOM6FfRKCGqmtWCZvLDlrTBxxiwN1NwCwhrw6jZFGCeCjDbAjL-bme8ajfjPbxPPAPvdwDEnEkfYLQu_ud4IzQVLHPllnM51D__9hAeTK2EqszVj5_m8ouY0e_XF-ZWPALnLqEO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733561630</pqid></control><display><type>article</type><title>What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Testa, L. ; Bhindi, R. ; Van Gaal, W.J. ; Latini, R.A. ; Pizzocri, S. ; Lanotte, S. ; Biondi Zoccai, G.G.L. ; Valgimigli, M. ; Laudisa, M.L. ; Brambilla, N. ; Banning, A.P. ; Bedogni, F.</creator><creatorcontrib>Testa, L. ; Bhindi, R. ; Van Gaal, W.J. ; Latini, R.A. ; Pizzocri, S. ; Lanotte, S. ; Biondi Zoccai, G.G.L. ; Valgimigli, M. ; Laudisa, M.L. ; Brambilla, N. ; Banning, A.P. ; Bedogni, F.</creatorcontrib><description>Thienopyridines are a class of drug targeting the platelet adenosine diphosphate 2 receptor. They have been shown to significantly reduce platelet activity exerting an important role in those clinical settings in which such an effect is beneficial. Ticlopidine was first to be introduced several years ago but it was quickly replaced by clopidogrel as it had a better risk/benefit profile. Recently, prasugrel has been developed and tested in several ex vivo studies and clinical trials showing able to provide a more powerful antiplatelet effect at the expense of a higher risk of bleeding complications. Great debate rose around its recent approval in the US as well as in Europe. This review aims at exploring the development and available clinical data of this third-generation thienopyridine while discussing its practical implementation in routine practice.</description><identifier>ISSN: 1460-2725</identifier><identifier>EISSN: 1460-2393</identifier><identifier>DOI: 10.1093/qjmed/hcq017</identifier><identifier>PMID: 20211848</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Biological and medical sciences ; Drug Evaluation, Preclinical ; General aspects ; Hemorrhage - complications ; Humans ; Medical sciences ; Piperazines - antagonists & inhibitors ; Piperazines - pharmacokinetics ; Piperazines - therapeutic use ; Platelet Aggregation Inhibitors - pharmacokinetics ; Platelet Aggregation Inhibitors - therapeutic use ; Prasugrel Hydrochloride ; Purinergic P2 Receptor Antagonists ; Randomized Controlled Trials as Topic ; Receptors, Purinergic P2 - therapeutic use ; Risk Factors ; Thiophenes - antagonists & inhibitors ; Thiophenes - pharmacokinetics ; Thiophenes - therapeutic use ; Ticlopidine - analogs & derivatives ; Ticlopidine - pharmacokinetics ; Ticlopidine - therapeutic use</subject><ispartof>QJM : An International Journal of Medicine, 2010-06, Vol.103 (6), p.367-377</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-1789327dfde104aed404c3aa554056d7a0b28216258c2a919bee5334cd69179c3</citedby><cites>FETCH-LOGICAL-c396t-1789327dfde104aed404c3aa554056d7a0b28216258c2a919bee5334cd69179c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22839031$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20211848$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Testa, L.</creatorcontrib><creatorcontrib>Bhindi, R.</creatorcontrib><creatorcontrib>Van Gaal, W.J.</creatorcontrib><creatorcontrib>Latini, R.A.</creatorcontrib><creatorcontrib>Pizzocri, S.</creatorcontrib><creatorcontrib>Lanotte, S.</creatorcontrib><creatorcontrib>Biondi Zoccai, G.G.L.</creatorcontrib><creatorcontrib>Valgimigli, M.</creatorcontrib><creatorcontrib>Laudisa, M.L.</creatorcontrib><creatorcontrib>Brambilla, N.</creatorcontrib><creatorcontrib>Banning, A.P.</creatorcontrib><creatorcontrib>Bedogni, F.</creatorcontrib><title>What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel</title><title>QJM : An International Journal of Medicine</title><addtitle>QJM</addtitle><description>Thienopyridines are a class of drug targeting the platelet adenosine diphosphate 2 receptor. They have been shown to significantly reduce platelet activity exerting an important role in those clinical settings in which such an effect is beneficial. Ticlopidine was first to be introduced several years ago but it was quickly replaced by clopidogrel as it had a better risk/benefit profile. Recently, prasugrel has been developed and tested in several ex vivo studies and clinical trials showing able to provide a more powerful antiplatelet effect at the expense of a higher risk of bleeding complications. Great debate rose around its recent approval in the US as well as in Europe. This review aims at exploring the development and available clinical data of this third-generation thienopyridine while discussing its practical implementation in routine practice.</description><subject>Biological and medical sciences</subject><subject>Drug Evaluation, Preclinical</subject><subject>General aspects</subject><subject>Hemorrhage - complications</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Piperazines - antagonists & inhibitors</subject><subject>Piperazines - pharmacokinetics</subject><subject>Piperazines - therapeutic use</subject><subject>Platelet Aggregation Inhibitors - pharmacokinetics</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Prasugrel Hydrochloride</subject><subject>Purinergic P2 Receptor Antagonists</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Receptors, Purinergic P2 - therapeutic use</subject><subject>Risk Factors</subject><subject>Thiophenes - antagonists & inhibitors</subject><subject>Thiophenes - pharmacokinetics</subject><subject>Thiophenes - therapeutic use</subject><subject>Ticlopidine - analogs & derivatives</subject><subject>Ticlopidine - pharmacokinetics</subject><subject>Ticlopidine - therapeutic use</subject><issn>1460-2725</issn><issn>1460-2393</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkU9v1DAQxSMEoqVw44x8Qb2Q1v8SxydUVbSlWqlCAoq4WBNn0nWbjbO2F9gvwWeut7sLJz_N_PxGeq8o3jJ6wqgWp8v7BXanc7ukTD0rDpmsacmFFs_3WvHqoHgV4z2lVCrZvCwOOOWMNbI5LP7eziERF0maIwkuPhDfEzcmHKPr1268I9MACQfM0Dh3rUvOj6TFtR87Ygc_uc7fBRw-kjMS1zHhApKzJOAvh78JZAiIDfmXhYHANAVwMat85OmgH3Cj8ziuNjavixc9DBHf7N6j4tvFp6_nV-Xs5vLz-dmstELXqWSq0YKrru-QUQnYSSqtAKgqSau6U0Bb3nBW86qxHDTTLWIlhLRdrZnSVhwVx1vfKfjlCmMyCxctDgOM6FfRKCGqmtWCZvLDlrTBxxiwN1NwCwhrw6jZFGCeCjDbAjL-bme8ajfjPbxPPAPvdwDEnEkfYLQu_ud4IzQVLHPllnM51D__9hAeTK2EqszVj5_m8ouY0e_XF-ZWPALnLqEO</recordid><startdate>20100601</startdate><enddate>20100601</enddate><creator>Testa, L.</creator><creator>Bhindi, R.</creator><creator>Van Gaal, W.J.</creator><creator>Latini, R.A.</creator><creator>Pizzocri, S.</creator><creator>Lanotte, S.</creator><creator>Biondi Zoccai, G.G.L.</creator><creator>Valgimigli, M.</creator><creator>Laudisa, M.L.</creator><creator>Brambilla, N.</creator><creator>Banning, A.P.</creator><creator>Bedogni, F.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100601</creationdate><title>What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel</title><author>Testa, L. ; Bhindi, R. ; Van Gaal, W.J. ; Latini, R.A. ; Pizzocri, S. ; Lanotte, S. ; Biondi Zoccai, G.G.L. ; Valgimigli, M. ; Laudisa, M.L. ; Brambilla, N. ; Banning, A.P. ; Bedogni, F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-1789327dfde104aed404c3aa554056d7a0b28216258c2a919bee5334cd69179c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Biological and medical sciences</topic><topic>Drug Evaluation, Preclinical</topic><topic>General aspects</topic><topic>Hemorrhage - complications</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Piperazines - antagonists & inhibitors</topic><topic>Piperazines - pharmacokinetics</topic><topic>Piperazines - therapeutic use</topic><topic>Platelet Aggregation Inhibitors - pharmacokinetics</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Prasugrel Hydrochloride</topic><topic>Purinergic P2 Receptor Antagonists</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Receptors, Purinergic P2 - therapeutic use</topic><topic>Risk Factors</topic><topic>Thiophenes - antagonists & inhibitors</topic><topic>Thiophenes - pharmacokinetics</topic><topic>Thiophenes - therapeutic use</topic><topic>Ticlopidine - analogs & derivatives</topic><topic>Ticlopidine - pharmacokinetics</topic><topic>Ticlopidine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Testa, L.</creatorcontrib><creatorcontrib>Bhindi, R.</creatorcontrib><creatorcontrib>Van Gaal, W.J.</creatorcontrib><creatorcontrib>Latini, R.A.</creatorcontrib><creatorcontrib>Pizzocri, S.</creatorcontrib><creatorcontrib>Lanotte, S.</creatorcontrib><creatorcontrib>Biondi Zoccai, G.G.L.</creatorcontrib><creatorcontrib>Valgimigli, M.</creatorcontrib><creatorcontrib>Laudisa, M.L.</creatorcontrib><creatorcontrib>Brambilla, N.</creatorcontrib><creatorcontrib>Banning, A.P.</creatorcontrib><creatorcontrib>Bedogni, F.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>QJM : An International Journal of Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Testa, L.</au><au>Bhindi, R.</au><au>Van Gaal, W.J.</au><au>Latini, R.A.</au><au>Pizzocri, S.</au><au>Lanotte, S.</au><au>Biondi Zoccai, G.G.L.</au><au>Valgimigli, M.</au><au>Laudisa, M.L.</au><au>Brambilla, N.</au><au>Banning, A.P.</au><au>Bedogni, F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel</atitle><jtitle>QJM : An International Journal of Medicine</jtitle><addtitle>QJM</addtitle><date>2010-06-01</date><risdate>2010</risdate><volume>103</volume><issue>6</issue><spage>367</spage><epage>377</epage><pages>367-377</pages><issn>1460-2725</issn><eissn>1460-2393</eissn><abstract>Thienopyridines are a class of drug targeting the platelet adenosine diphosphate 2 receptor. They have been shown to significantly reduce platelet activity exerting an important role in those clinical settings in which such an effect is beneficial. Ticlopidine was first to be introduced several years ago but it was quickly replaced by clopidogrel as it had a better risk/benefit profile. Recently, prasugrel has been developed and tested in several ex vivo studies and clinical trials showing able to provide a more powerful antiplatelet effect at the expense of a higher risk of bleeding complications. Great debate rose around its recent approval in the US as well as in Europe. This review aims at exploring the development and available clinical data of this third-generation thienopyridine while discussing its practical implementation in routine practice.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>20211848</pmid><doi>10.1093/qjmed/hcq017</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1460-2725 |
| ispartof | QJM : An International Journal of Medicine, 2010-06, Vol.103 (6), p.367-377 |
| issn | 1460-2725 1460-2393 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733561630 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Biological and medical sciences Drug Evaluation, Preclinical General aspects Hemorrhage - complications Humans Medical sciences Piperazines - antagonists & inhibitors Piperazines - pharmacokinetics Piperazines - therapeutic use Platelet Aggregation Inhibitors - pharmacokinetics Platelet Aggregation Inhibitors - therapeutic use Prasugrel Hydrochloride Purinergic P2 Receptor Antagonists Randomized Controlled Trials as Topic Receptors, Purinergic P2 - therapeutic use Risk Factors Thiophenes - antagonists & inhibitors Thiophenes - pharmacokinetics Thiophenes - therapeutic use Ticlopidine - analogs & derivatives Ticlopidine - pharmacokinetics Ticlopidine - therapeutic use |
| title | What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T18%3A55%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=What%20is%20the%20risk%20of%20intensifying%20platelet%20inhibition%20beyond%20clopidogrel?%20A%20systematic%20review%20and%20a%20critical%20appraisal%20of%20the%20role%20of%20prasugrel&rft.jtitle=QJM%20:%20An%20International%20Journal%20of%20Medicine&rft.au=Testa,%20L.&rft.date=2010-06-01&rft.volume=103&rft.issue=6&rft.spage=367&rft.epage=377&rft.pages=367-377&rft.issn=1460-2725&rft.eissn=1460-2393&rft_id=info:doi/10.1093/qjmed/hcq017&rft_dat=%3Cproquest_cross%3E733561630%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733561630&rft_id=info:pmid/20211848&rfr_iscdi=true |